Platform Communications: Abstract Book - 31st International Symposium on ALS/MND (Complete printable file)

Acknowledgements

Funding from Cure Alzheimer’s Fund and JPB Foundation. Financial Interest in Amylyx Pharma, AZTherapies, Cognitive Clarity, Neurogenetic Pharmaceuticals, Chromadex, React Neuro.

Acknowledgements

We thank the Alberti lab and the Brandman lab for their collaboration. We thank CIGS for technical support with microscopy experiments.

Acknowledgements

We would like to thank patients for taking part in the study. The study was sponsored by Orion Pharma Orion Corporation.

Acknowledgements

This clinical trial received funding from the California Institute for Regenerative Medicine (CIRM CLIN2-0989) and support for a biomarker study from IAMALS and ALSA.

Acknowledgments

We thank the participants and the Trajectories of Outcomes in Neurological Conditions study group for their contribution of data described in this presentation. The TONiC-MND study is supported by the Motor Neurone Disease Association, NIHR CLRN, and the Neurological Disability Fund 4530.

Acknowledgements

Authors thank ALS Canada and Brain Canada, ALS Association, Target ALS.

Acknowledgements

AC serves as advisor for Mitsubishi Tanabe, Roche, Biogen, and Cytokinetics and received a research grant from Italfarmaco. SF, TC, WF, TF are employees/stockholders of Biogen. FB is employee/stockholder of Ionis Pharmaceuticals, Inc.

Acknowledgements

This work was supported by NIH grants R35NS097263 and R01AG064690 and the Robert Packard Center for ALS Research at Johns Hopkins. A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics and Third Rock Ventures and is a scientific founder of Maze Therapeutics.

Acknowledgements

This study was funded by the ALS Society of Canada and philanthropic gifts.